Optimizing panel-based tumor mutational burden (TMB) measurement von Budczies, J., Allgäuer, M., Litchfield, K., Rempel, E., Christopoulos, P., Kazdal, D., Endris, V., Thomas, M., Fröhling, S., Peters, S., Swanton, C., Schirmacher, P., Stenzinger, A.

Volltext

Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia von Bochtler, T, Fröhling, S, Krämer, A

Volltext

Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours von van der Graaf, W.T.A., Tesselaar, M.E.T., McVeigh, T.P., Oyen, W.J.G., Fröhling, S.

Volltext

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia von Rudat, S., Pfaus, A., Cheng, Y. Y., Holtmann, J., Ellegast, J. M., Bühler, C., Marcantonio, D. Di, Martinez, E., Göllner, S., Wickenhauser, C., Müller-Tidow, C., Lutz, C., Bullinger, L., Milsom, M. D., Sykes, S. M., Fröhling, S., Scholl, C.

Volltext

Real‐world data for precision cancer medicine—A European perspective von Christopoulos, Petros, Schlenk, Richard, Kazdal, Daniel, Blasi, Miriam, Lennerz, Jochen, Shah, Rajiv, Budczies, Jan, Malek, Nisar, Fröhling, Stefan, Rosenquist, Richard, Schirmacher, Peter, Bozorgmehr, Farastuk, Kuon, Jonas, Reck, Martin, Thomas, Michael, Stenzinger, Albrecht

Volltext

Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial von Seidensaal, K., Kieser, M., Hommertgen, A., Jaekel, C., Harrabi, S. B., Herfarth, K., Mechtesheimer, G., Lehner, B., Schneider, M., Nienhueser, H., Froehling, S., Egerer, G., Debus, J., Uhl, M.

Volltext

Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution von Seidensaal, K., Harrabi, S. B., Weykamp, F., Herfarth, K., Welzel, T., Mechtersheimer, G., Lehner, B., Schneider, M., Froehling, S., Egerer, G., Debus, J., Uhl, M.

Volltext

High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma von Westphal, D., Garzarolli, M., Sergon, M., Horak, P., Hutter, B., Becker, J.C., Wiegel, M., Maczey, E., Blum, S., Grosche‐Schlee, S., Rütten, A., Ugurel, S., Stenzinger, A., Glimm, H., Aust, D., Baretton, G., Beissert, S., Fröhling, S., Redler, S., Surowy, H., Meier, F.

Volltext

Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway von Maurus, K., Kosnopfel, C., Kneitz, H., Appenzeller, S., Schrama, D., Glutsch, V., Roth, S., Gerhard‐Hartmann, E., Rosenfeldt, M., Möhrmann, L., Fröhlich, M., Hübschmann, D., Stenzinger, A., Glimm, H., Fröhling, S., Goebeler, M., Rosenwald, A., Kutzner, H., Schilling, B.

Volltext

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD) von Rempel, E., Kluck, K., Beck, S., Ourailidis, I., Kazdal, D., Neumann, O., Volckmar, A. L., Kirchner, M., Goldschmid, H., Pfarr, N., Weichert, W., Hübschmann, D., Fröhling, S., Sutter, C., Schaaf, C. P., Schirmacher, P., Endris, V., Stenzinger, A., Budczies, J.

Volltext

JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia von Zhou, C, Martinez, E, Di Marcantonio, D, Solanki-Patel, N, Aghayev, T, Peri, S, Ferraro, F, Skorski, T, Scholl, C, Fröhling, S, Balachandran, S, Wiest, D L, Sykes, S M

Volltext

Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance von Rücker, F G, Russ, A C, Cocciardi, S, Kett, H, Schlenk, R F, Botzenhardt, U, Langer, C, Krauter, J, Fröhling, S, Schlegelberger, B, Ganser, A, Lichter, P, Zenz, T, Döhner, H, Döhner, K, Bullinger, L

Volltext

Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma von Dieter, S.M., Heining, C., Agaimy, A., Huebschmann, D., Bonekamp, D., Hutter, B., Ehrenberg, K.R., Fröhlich, M., Schlesner, M., Scholl, C., Schlemmer, H.-P., Wolf, S., Mavratzas, A., Jung, C.S., Gröschel, S., von Kalle, C., Eils, R., Brors, B., Penzel, R., Kriegsmann, M., Reuss, D.E., Schirmacher, P., Stenzinger, A., Federspil, P.A., Weichert, W., Glimm, H., Fröhling, S.

Volltext

Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms von Apostolidis, L., Kreutzfeldt, S., Oles, M., Gieldon, L., Heining, C., Horak, P., Hutter, B., Fröhlich, M., Klink, B., Lamping, M., Uhrig, S., Stenzinger, A., Winkler, E.C., Wiedenmann, B., Jäger, D., Schröck, E., Keilholz, U., Pavel, M.E., Glimm, H., Fröhling, S.

Volltext

Phase iii study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia von SCHLENK, R. F, FRÖHLING, S, PRALLE, H, MERGENTHALER, H. G, HANSEL, M, KOLLER, E, KIRCHEN, H, PREISS, J, SALWENDER, H, BIEDERMANN, H. G, KREMERS, S, GRIESINGER, F, HARTMANN, F, BENNER, A, ADDAMO, B, DÖHNER, K, HAAS, R, DÖHNER, H, FISCHER, Jth, GLASMACHER, A, DEL VALLE, F, GRIMMINGER, W, GÖTZE, K, WATERHOUSE, C, SCHOCH, R

Volltext

71: Targeted cancer genetics von Von Kalle, C, Fröhling, S, Glimm, H, Pfister, S.M, Zenz, T

Volltext

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia von Sandhöfer, N, Metzeler, K H, Rothenberg, M, Herold, T, Tiedt, S, Groiß, V, Carlet, M, Walter, G, Hinrichsen, T, Wachter, O, Grunert, M, Schneider, S, Subklewe, M, Dufour, A, Fröhling, S, Klein, H-G, Hiddemann, W, Jeremias, I, Spiekermann, K

Volltext

TRANSCRIPTIONAL AND GENOMIC INTRA‐TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA von Roider, T., Frauhammer, F., Seufert, J., Bordas, M., Stolarczyk, M., Rabe, S., Malm, J., Bruch, P., Hundemer, M., Rippe, K., Goeppert, B., Seiffert, M., Brors, B., Mechtersheimer, G., Müller‐Tidow, C., Fröhling, S., Schlesner, M., Huber, W., Anders, S., Dietrich, S.

Volltext

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial von Heilig, C.E., Horak, P., Kreutzfeldt, S., Teleanu, V., Mock, A., Renner, M., Bhatti, I.A., Hutter, B., Hüllein, J., Fröhlich, M., Uhrig, S., Süße, H., Heiligenthal, L., Ochsenreither, S., Illert, A.L., Vogel, A., Desuki, A., Heinemann, V., Heidegger, S., Bitzer, M., Scheytt, M., Brors, B., Hübschmann, D., Baretton, G., Stenzinger, A., Steindorf, K., Benner, A., Jäger, D., Heining, C., Glimm, H., Fröhling, S., Schlenk, R.F.

Volltext

Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial von SCHLENK, R. F, BENNER, A, GRIMMINGER, W, PREISS, J, HENSEL, M, FRÖHLING, S, DÖHNER, K, HAAS, R, DÖHNER, H, HARTMANN, F, DEL VALLE, F, WEBER, C, PRALLE, H, FISCHER, J. Th, GUNZER, U, PEZZUTTO, A, WEBER, W

Volltext